Chen Zhaozhao, Hu Yu, Mei Heng
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan 430022, China.
Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan 430022, China.
Pharmaceuticals (Basel). 2024 Jan 22;17(1):139. doi: 10.3390/ph17010139.
Chimeric antigen receptor T cell (CAR-T) therapy has emerged as a groundbreaking approach in cancer treatment, showcasing remarkable efficacy. However, the formidable challenge lies in taming the formidable side effects associated with this innovative therapy, among which cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) and on-target off-tumor toxicities (OTOT) are typical representatives. Championing the next frontier in cellular immunotherapy, this comprehensive review embarks on an artistic exploration of leveraging biomaterials to meticulously navigate the intricate landscape of CAR-T cell therapy. Unraveling the tapestry of potential toxicities, our discourse unveils a symphony of innovative strategies designed to elevate the safety profile of this revolutionary therapeutic approach. Through the lens of advanced medical science, we illuminate the promise of biomaterial interventions in sculpting a safer and more efficacious path for CAR-T cell therapy, transcending the boundaries of conventional treatment paradigms.
嵌合抗原受体T细胞（CAR-T）疗法已成为癌症治疗中一种开创性的方法，展现出显著的疗效。然而，巨大的挑战在于控制与这种创新疗法相关的严重副作用，其中细胞因子释放综合征（CRS）、免疫效应细胞相关神经毒性综合征（ICANS）和靶向非肿瘤毒性（OTOT）是典型代表。作为细胞免疫治疗的下一个前沿领域，这篇综述开始了一项艺术探索，即利用生物材料精心应对CAR-T细胞治疗的复杂局面。通过剖析潜在毒性的全貌，我们的论述揭示了一系列创新策略，旨在提升这种革命性治疗方法的安全性。透过先进医学科学的视角，我们阐明了生物材料干预在为CAR-T细胞治疗塑造更安全、更有效的路径方面的前景，超越了传统治疗模式的界限。
